FIELD: medicine, pharmaceutics.
SUBSTANCE: claimed are: pharmaceutical combination for treating proliferative disease, including a) pyrimidylaminobenzamide of formula A compound 
and b) kinase Thr315lle inhibitor, representing (3-trifluoromethyl-phenyl)amide 6-(2-aminopyrimidin-4yloxy)naphthalene-1-carboxylic acid, or [6-[[1-[[4-[(4-methyl-1-piperasinyl)methyl]-3-(trifluoromethyl)phenyl-amino]carbonyl]-1H-indol-5-yl]oxy]-4-pyrimidyl]acetamide, N-[3-[[1-[6-(cyclopropylamino)-4-pyrimidinyl]-1H-imidasol-2-yl]amino]-4-methylphenyl]-3-(4-methyl-1H-imidazole-1yl)-5-(trifluoromethyl)benzamide, AP24534 or their combinations in sinergetically effective quantity, method of treatment or prevention of proliferative disease with application of such combination and methods of treating leucosis (versions).
EFFECT: combination suppresses any mutant forms of oncogenic protein Bcr-Abl, makes it possible to treat proliferative diseases in which super-expression of said gene is observed, in particular, leucoses.
7 cl
